The Active Molecule Is Not the Phytochemical You Swallow: Reframing Pharmacology Around Metabolites and Exposure

Download PDF

Natural-product pharmacology conventionally begins with the isolated, formulated, or ingested phytochemical and carries that molecular identity forward into screening, target prediction, docking, and mechanistic interpretation. For orally administered compounds, however, the molecule entering an assay or computational model may not be the species that reaches systemic circulation or the relevant biological site. Intestinal transformation, microbial metabolism, phase I and phase II reactions, transporter-dependent disposition, conjugation, and local deconjugation generate multiple molecular entities with distinct exposure profiles and potentially distinct pharmacology. This mechanistic perspective argues that natural-product pharmacology should distinguish oral identity from exposure identity and, ultimately, from the molecular identity implicated at the proposed site of action. Evidence from human metabolomics, pharmacokinetics, microbial xenobiotic metabolism, conjugate disposition, tissue pharmacokinetics, and metabolite bioanalysis is integrated into a proposed exposure-weighted molecular-ensemble framework. The framework treats predicted metabolites, measured circulating species, tissue-accessible molecules, and experimentally supported target ligands as different evidential states rather than interchangeable evidence of mechanism. It also explains why parent-only screening or docking may prioritize a chemically plausible but biologically mis-specified ligand. The argument remains bounded: parent compounds can be pharmacologically relevant, local gastrointestinal mechanisms may not require systemic exposure, conjugates are not uniformly active or inactive, and metabolite prediction does not establish formation or target engagement. Mechanistic attribution should follow the molecular species that plausibly reaches the biology being explained.